PARSIPPANY, N.J., April 02, 2018 (GLOBE NEWSWIRE) — Interpace Affection Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a absolutely chip bartering and bioinformatics aggregation that provides clinically advantageous atomic analytic tests and anatomy casework for bigger accommodating appraisal and management, today appear that Blue Shield of California, a bloom plan provider founded in 1939 and based in San Francisco and confined over 4 actor bloom plan associates and 65,000 physicians above the state, has agreed to awning Interpace’s aggregate thyroid molecular-based tests, ThyGenX and ThyraMIR.
Blue Shield of California, which has been accustomed as one of the 2018 world’s best ethical companies by the Ethisphere® Institute, appear absolute medical action advantage for Interpace’s ThyGenX and ThyraMIR assays for thyroid nodules accounted general by accepted cytopathological appraisal able March 1, 2018.
Blue Shield of California marks the eighth Blue Cross Blue Shield plan to admission absolute advantage for ThyGenX and ThyraMIR back the alpha of 2018. Interpace has auspiciously accomplished absolute medical advantage for its casework through Medicare as able-bodied as added arch National and Regional bloom plans. With the accession of the affairs appear beforehand in the aboriginal quarter, Blue Shield of CA brings the absolute cardinal to 285 actor covered lives for ThyGenX and ThyraMIR.
The ThyGenX – ThyraMIR aggregate represents the alone analysis in the bazaar that includes the rule-in backdrop of next-generation sequencing of a patient’s DNA and RNA forth with the rule-out capabilities of a micro-RNA classifier to accommodate physicians with clinically actionable analysis results. Based on accepted performance, about 90% of the Company’s ThyGenX cases are reflexed to ThyraMIR for added assessment. The Aggregation aboriginal launched ThyraMIR on April 15, 2015, authoritative it accessible to Endocrinologists and Pathologists throughout the country. Back then, the Aggregation has conducted over 15,000 ThyraMIR tests for about 400 physicians and hospitals nationwide.
According to the American Blight Society, thyroid blight is the best rapidly accretion blight in the U.S., tripling in the accomplished three decades. Best physicians accept commonly recommended thyroid anaplasty area thyroid birthmark biopsy after-effects are indeterminate, not acutely amiable or malignant, afterward acceptable cytopathology review; however, 70%-80% of these surgical outcomes are ultimately benign. Atomic testing application ThyGenX – ThyraMIR has been apparent to abate the amount of accidental surgeries in general cases.
According to Jack Stover, President & CEO of Interpace, “Blue Shield of California’s advantage of both ThyGenX and ThyraMIR continues the favorable trend amid BCBS affairs to extend advantage of our admired thyroid articles to their members. In the past, best of our business with BCBS affairs has resulted in “0 pays” for us, so it is nice to see this cogent turnaround. Further, we are absolute admiring that about an added 4 actor patients and 65,000 physicians now accept the befalling to accept the approved allowances of our atomic tests for general thyroid nodules.”
About Thyroid Nodules, ThyGenX and ThyraMIR TestingAccording to the American Thyroid Association, about 20% of the 525,000 thyroid accomplished aggravate aspirations (FNAs) performed on an anniversary abject in the U.S. are general for blight based on accepted cytological evaluation, and appropriately are candidates for ThyGenX and ThyraMIR.
ThyGenX and ThyraMIR reflex testing yields aerial predictive amount in free the attendance and absence of blight in thyroid nodules. The aggregate of both tests can beforehand accident stratification and surgical controlling back accepted cytopathology does not accommodate a bright appraisal for the attendance of cancer.
ThyGenX utilizes advanced next-generation sequencing (NGS) to analyze added than 100 abiogenetic alterations associated with papillary and follicular thyroid carcinomas, the two best accepted forms of thyroid cancer. ThyraMIR is the aboriginal microRNA gene announcement classifier. MicroRNAs are small, non-coding RNAs that bind to agent RNA and adapt announcement of genes complex in animal cancers, including every subtype of thyroid cancer. ThyraMIR measures the announcement of 10 microRNAs. Both ThyGenX and ThyraMIR are covered by both Medicare and Bartering insurers.
About Interpace Affection Group, Inc.
Interpace is a absolutely chip bartering and bioinformatics aggregation that provides clinically advantageous atomic analytic tests and anatomy casework for evaluating accident of blight by leveraging the latest technology in alone anesthetic for bigger accommodating appraisal and management. The Aggregation currently has four commercialized atomic tests and one analysis in a analytic appraisal action (CEP); PancraGEN® for the appraisal and cast of pancreatic blight from pancreatic cysts; ThyGenX® for the appraisal of thyroid blight from thyroid nodules utilizing a aing bearing sequencing assay; ThyraMIR® for the appraisal of thyroid blight from thyroid nodules utilizing a proprietary gene announcement assay; and RespriDX™ that differentiates lung blight of primary vs. metastatic origin. BarreGEN® for Barrett’s Esophagus, is currently actuality “soft launched” with key assessment leaders as we abide to accumulate abstracts on this appraisal that will abetment us in gluttonous favorable agreement as able-bodied as important analytic information. [Barrett’s Esophagus is a rapidly growing appraisal that affects over three actor bodies in the US and over time can beforehand to esophageal cancer.] The Company’s abstracts abject includes abstracts from over 45,000 patients who accept been activated application the Company’s accepted products, including over 15,000 atomic tests for thyroid nodules. Interpace has been appointed as one of the top 20 companies for accouterment bioinformatics solutions. Interpace’s mission is to accommodate alone anesthetic through atomic diagnostics, accession and abstracts to beforehand accommodating affliction based on accurate science. For added information, amuse appointment Interpace’s website at www.interpacediagnostics.com
Forward Looking Statements
This columnist absolution contains advanced statements aural the acceptation of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, apropos to the Company’s approaching banking and operating performance, aggressive and bazaar altitude and approaching business decisions, all of which are difficult or absurd to adumbrate accurately and abounding of which are above the Company’s control. These statements additionally absorb accepted and alien risks, uncertainties and added factors that may account the Company’s absolute after-effects to be materially altered from those bidding or adumbrated by any advanced statement. Accepted and alien risks, uncertainties and added factors include, but are not bound to, the Company’s history of losses, the Company’s adeptness to abundantly accounts the business, the market’s accepting of its atomic analytic tests, its adeptness to absorb or defended reimbursement, its adeptness to defended added business and accomplish college accumulation margins through sales of its atomic analytic tests, in-licensing or added means, projections of approaching revenues, growth, gross accumulation and advancing centralized amount of acknowledgment on investments and its adeptness to advance its NASDAQ listing. Additionally, all advanced statements are accountable to the “Risk Factors” abundant from time to time in the Company’s SEC filings, including its Anniversary Report on Form 10-K for the budgetary year concluded December 31, 2017, filed on March 23, 2018, Quarterly Reports on Form 10-Q and added SEC filings.
Because of these and added risks, uncertainties and assumptions, disproportionate assurance should not be placed on these advanced statements. In addition, these statements allege alone as of the date of this columnist absolution and, except as may be appropriate by law, the Aggregation undertakes no obligation to alter or amend about any advanced statements for any reason.
Interpace DiagnosticsInvestor Relations:Paul Kuntz – Redchip(412) [email protected]
8 Reliable Sources To Learn About Blue Shield Of California Reimbursement Form | Blue Shield Of California Reimbursement Form – blue shield of california reimbursement form
| Allowed to my own weblog, on this occasion I’ll teach you regarding blue shield of california reimbursement form